Skip to main content
Premium Trial:

Request an Annual Quote

Neogenomics Revenues Grow 49 Percent, Sees Profit in Q2

NEW YORK (GenomeWeb News) – Cancer genetics testing company Neogenomics said on Thursday that revenues during the second quarter rose 49 percent year over year as test volume increased 57 percent.

For the period ended June 30, revenues totaled $15.6 million, up from $10.5 million a year ago as the number of tests performed jumped to 28,846 from 18,358.

R&D costs increased by more than three-fold to $528,000 from $172,000 during the second quarter of 2011 as a result of new test development. According to Douglas VanOort, the Ft. Myers, Fla.-based company has launched 20 new molecular tests in 2012 so far and expects to launch between 15 and 20 more assays, including the NeoType Cancer Profiles, by the end of the year.

SG&A costs rose to $6.0 million, up 30 percent from $4.6 million.

Neogenomics recorded a profit of $551,000, or $.01 per share, compared to a loss of $293,000, or $.01 per share, a year ago. The company ended the quarter with $2.6 million in cash and cash equivalents.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.